Tyrosine kinase

Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors

Retrieved on: 
Wednesday, February 10, 2021
Tyrosine kinase receptors, Oncogenes, Branches of biology, Cancer, ErbB, Epidermal growth factor receptor, HER2/neu, Protein kinase inhibitor, Tyrosine kinase, ERBB4, Spectrum Pharmaceuticals, AEE788

EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.

Key Points: 
  • EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.
  • Under the terms of the agreement, Apollomics has the exclusive rights to develop and commercialize EO1001 globally, except in China, Hong Kong and Taiwan.
  • EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.
  • Edison Oncology was founded in 2018 by experienced life science industry veterans to develop and commercialize new therapies targeting the fight against cancer.

Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors

Tyrosine kinase receptors, Oncogenes, Branches of biology, Cancer, ErbB, Epidermal growth factor receptor, HER2/neu, Protein kinase inhibitor, Tyrosine kinase, ERBB4, Spectrum Pharmaceuticals, AEE788

EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.

Key Points: 
  • EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.
  • Under the terms of the agreement, Apollomics has the exclusive rights to develop and commercialize EO1001 globally, except in China, Hong Kong and Taiwan.
  • EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.
  • Edison Oncology was founded in 2018 by experienced life science industry veterans to develop and commercialize new therapies targeting the fight against cancer.

Global Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Insight Report 2020 Featuring Genosco, Portola Pharmaceuticals, GlaxoSmithKline, FUJIFILM, TopiVert, Takeda Oncology & Asana BioSciences - ResearchAndMarkets.com

Retrieved on: 
Friday, February 5, 2021
Health, Pharmaceutical, Tyrosine kinases, Enzymes, Tyrosine-protein kinase SYK, Tyrosine kinase, Entospletinib, Cerdulatinib

The "Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2020" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen Tyrosine Kinase (SYK) Inhibitors pipeline landscape.
  • Spleen Tyrosine Kinase (SYK) Inhibitors: Therapeutic Assessment
    This segment of the report provides insights about the different Spleen Tyrosine Kinase (SYK) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • The companies which have their Spleen Tyrosine Kinase (SYK) Inhibitors drug candidates in the most advanced stage, i.e.

Asana BioSciences’ Gusacitinib Granted FDA Fast-Track Designation for Moderate-to-Severe Chronic Hand Eczema

Retrieved on: 
Wednesday, February 3, 2021
Research, FDA, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Oncology, Enzymes, Tyrosine-protein kinase SYK, Tyrosine kinase, Jak, Drugs, Tyrosine kinase inhibitors, Orphan drugs, Protein kinase inhibitors, Indazoles, Cerdulatinib, Janus kinase inhibitor

Asana BioSciences, a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast-Track designation to Asanas gusacitinib (ASN002), an investigational oral, dual inhibitor of Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK), for the treatment of moderate-to-severe Chronic Hand Eczema (CHE).

Key Points: 
  • Asana BioSciences, a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast-Track designation to Asanas gusacitinib (ASN002), an investigational oral, dual inhibitor of Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK), for the treatment of moderate-to-severe Chronic Hand Eczema (CHE).
  • Patients with CHE suffer greatly from this disease, which limits their ability to work and perform activities of daily living.
  • There are no approved treatments for patients suffering from CHE in the U.S. and in many other major markets.
  • We are pleased that the FDA has granted Fast-Track designation to gusacitinib.

High Cancer Prevalence and Rise in Number of Pharmacies to Boost Growth Rate of Kinase Inhibitors Market: TMR

Retrieved on: 
Tuesday, January 26, 2021
Enzymes, Protein kinases, Tyrosine kinase inhibitor, Tyrosine kinase, Protein kinase, Kinase, Serine/threonine-specific protein kinase, mTOR inhibitors, MAP kinase kinase kinase

The growing utilization of kinase inhibitors in cancer therapies may bring immense growth prospects for the kinase inhibitors market.

Key Points: 
  • The growing utilization of kinase inhibitors in cancer therapies may bring immense growth prospects for the kinase inhibitors market.
  • Various drug discovery programs have led to effective kinase inhibitors, thus influencing the growth of the kinase inhibitors market to a great extent.
  • The utilization of tyrosine kinase inhibitors for treating a plethora of autoimmune and inflammatory skin diseases may bring expansive growth prospects for the kinase inhibitors market.
  • Gain insights into theKinase Inhibitors Market (Type: Non-receptor Tyrosine Kinase Inhibitors, Receptor Tyrosine Kinase Inhibitors, Multikinase Inhibitors, Serine/Threonine Kinase Inhibitors, Protein Kinase C Inhibitors, RHO Kinase Inhibitors, and Others; Application: Oncology, Inflammatory Diseases, and Others; and Distribution Channel: Hospital Pharmacies, Independent Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 at https://www.transparencymarketresearch.com/report-toc/818
    North America's kinase inhibitors market is extrapolated to invite tremendous growth opportunities across the assessment period.

High Cancer Prevalence and Rise in Number of Pharmacies to Boost Growth Rate of Kinase Inhibitors Market: TMR

Retrieved on: 
Tuesday, January 26, 2021
Enzymes, Protein kinases, Tyrosine kinase inhibitor, Tyrosine kinase, Protein kinase, Kinase, Serine/threonine-specific protein kinase, mTOR inhibitors, MAP kinase kinase kinase

The growing utilization of kinase inhibitors in cancer therapies may bring immense growth prospects for the kinase inhibitors market.

Key Points: 
  • The growing utilization of kinase inhibitors in cancer therapies may bring immense growth prospects for the kinase inhibitors market.
  • Various drug discovery programs have led to effective kinase inhibitors, thus influencing the growth of the kinase inhibitors market to a great extent.
  • The utilization of tyrosine kinase inhibitors for treating a plethora of autoimmune and inflammatory skin diseases may bring expansive growth prospects for the kinase inhibitors market.
  • Gain insights into theKinase Inhibitors Market (Type: Non-receptor Tyrosine Kinase Inhibitors, Receptor Tyrosine Kinase Inhibitors, Multikinase Inhibitors, Serine/Threonine Kinase Inhibitors, Protein Kinase C Inhibitors, RHO Kinase Inhibitors, and Others; Application: Oncology, Inflammatory Diseases, and Others; and Distribution Channel: Hospital Pharmacies, Independent Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 at https://www.transparencymarketresearch.com/report-toc/818
    North America's kinase inhibitors market is extrapolated to invite tremendous growth opportunities across the assessment period.

Fenebrutinib (GDC-0853, RG7845): An Orally Administered Bruton's tyrosine Kinase (BTK) Inhibitor Designed to Block B Cell Proliferation - Emerging Insights and Market Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 23, 2020
Health, Pharmaceutical, Tyrosine kinases, Bruton's tyrosine kinase, BTK, Tyrosine kinase

"FENEBRUTINIB- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Chronic Spontaneous Urticaria in 7 Major Markets.

Key Points: 
  • "FENEBRUTINIB- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Chronic Spontaneous Urticaria in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • Fenebrutinib (GDC-0853, RG7845) is an orally administered Bruton's tyrosine kinase (BTK) inhibitor designed to block B cell proliferation and the resulting excessive immune response seen in autoimmune disorders.
  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.

LOU064: An Oral Bruton's Tyrosine Kinase (BTK) Inhibitor - Emerging Insights and Market Forecasts 2020-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 23, 2020
Health, Pharmaceutical, Bruton's tyrosine kinase, Tyrosine kinase, Hives, BTK

"LOU064- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Chronic Spontaneous Urticaria in 7 Major Markets.

Key Points: 
  • "LOU064- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Chronic Spontaneous Urticaria in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • LOU064 is an oral Bruton's tyrosine kinase (BTK) inhibitor.
  • Other emerging products for Chronic Spontaneous Urticaria are giving market competition to LOU064 and launch of late-stage emerging therapies in the near future will significantly impact the market.

AB Science issues a corrective press release regarding adverse events information from study AB09004 reported on December 16, 2020

Retrieved on: 
Thursday, December 17, 2020
Medicine, Clinical medicine, Cancer, Protein kinase inhibitors, Masitinib, Tyrosine kinases, Cancer treatments, Tyrosine kinase, Kinase, Oncology, ABL, Immunotherapy

AB Science SA (Euronext - FR0010557264 - AB) today announced that the press release issued on December 16, 2020 regarding the results from study AB09004, which evaluated masitinib in the treatment of Alzheimer disease, contained a material error in the adverse events information reported.

Key Points: 
  • AB Science SA (Euronext - FR0010557264 - AB) today announced that the press release issued on December 16, 2020 regarding the results from study AB09004, which evaluated masitinib in the treatment of Alzheimer disease, contained a material error in the adverse events information reported.
  • Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases.
  • In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy.
  • AB Science disclaims any obligationor undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq.

Kite’s Tecartus™ (KTE-X19) Granted Conditional Marketing Authorization for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma in Europe

Retrieved on: 
Wednesday, December 16, 2020
Biotechnology, Hospitals, Health, Pharmaceutical, Oncology, Clinical medicine, Cancer treatments, Medicine, Lymphoma, Orphan drugs, Non-Hodgkin lymphoma, Breakthrough therapy, Gene therapy, Bruton's tyrosine kinase, Mantle cell lymphoma, Tyrosine kinase, Chimeric antigen receptor T cell

Tecartus is a chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Brutons tyrosine kinase (BTK) inhibitor.

Key Points: 
  • Tecartus is a chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Brutons tyrosine kinase (BTK) inhibitor.
  • Conditional authorization is granted in the interest of public health where the benefit of immediate availability outweighs the risk of less comprehensive data available.
  • The availability of this first cell therapy for relapsed or refractory mantle cell lymphoma, following at least two lines of systemic therapy including a BTK inhibitor, provides an important option for patients in Europe.
  • In Europe, it is estimated that at least 7,400 people are diagnosed with mantle cell lymphoma each year.